位置:成果数据库 > 期刊 > 期刊详情页
鼻粘膜免疫融合蛋白Hsp65-6×p277预防NOD小鼠1型糖尿病的发生
  • ISSN号:1009-2501
  • 期刊名称:《中国临床药理学与治疗学》
  • 时间:0
  • 分类:R966[医药卫生—药理学;医药卫生—药学] R587.1[医药卫生—内分泌;医药卫生—临床医学;医药卫生—内科学]
  • 作者机构:[1]中国药科大学生命科学与技术学院,江苏南京210009
  • 相关基金:Supported by the National High Technology "863" Programs of China (No.2002AA217031-2);National Natural Science Foundation of China (No.30270298);Natural Science Foundation of Jiangsu (No.BK95092309;No.BG2001011)
中文摘要:

目的:提高多肽p277的免疫原性,从而提高其对自身免疫性糖尿病的预防作用.方法:将p277 6次重复与Hsp 65融合置于pET28a中构建重组Hsp 65-6×p277表达质粒.该重组质粒在大肠杆菌BL21中以高效可溶形式表达.依次通过细胞裂解、硫酸铵沉淀、双蒸水透析、DEAE纤维素52柱层析纯化获得目的蛋白.用纯化后的融合蛋白Hsp 65-6×p277通过鼻腔给药方式,在不添加任何佐剂的情况下3次免疫4周龄雌性NOD小鼠.每月眼角取血,检测抗体和血糖浓度.结果:初步药效学实验表明融合蛋白Hsp 65-6×p277可抑制NOD小鼠中1型糖尿病的发生.结论:融合蛋白Hsp 65-6×p277有可能发展成为一种具有防治胰岛素依赖性糖尿病作用的疫苗.

英文摘要:

AIM: To improve the prevent efficacy of peptide p277 in autoimmune diabetes. METHODS: The recombinant expression plasmid pET28-Hsp65-6×p277 was constructed by inserting 6×p277 which were amplified by PCR into the vector pET28-Hsp65. The plasmid pET28-Hsp65-6×p277 was transformed into E.coli BL21 (DE3) and the fusion protein (Hsp65-6×p277) was expressed effectively as soluble protein after inducing by lactose. The fusion protein was purified and then used to immunize 4-week old female NOD mice with three times of i.n. inoculations in the absence of adjuvants. Serum samples from the immunized mice were collected at monthly interval. The concentrations of blood glucose and antibodies were measured by automatic analyzer. RESULTS: Administration with the Hsp65-6×p277 to NOD mice could prevent the development of diabetes. CONCLUSION: The fusion protein Hsp65-6×p277 might be further developed to a vaccine against insulin-dependent diabetes mellitus.

同期刊论文项目
同项目期刊论文
期刊信息
  • 《中国临床药理学与治疗学》
  • 主管单位:中国科学技术协会
  • 主办单位:中国药理学会
  • 主编:孙瑞元
  • 地址:安徽芜湖市皖南医学院弋矶山医院
  • 邮编:241001
  • 邮箱:cjcpt96@163.com
  • 电话:0553-5738350 5739333
  • 国际标准刊号:ISSN:1009-2501
  • 国内统一刊号:ISSN:34-1206/R
  • 邮发代号:26-165
  • 获奖情况:
  • 国内外数据库收录:
  • 美国化学文摘(网络版),波兰哥白尼索引
  • 被引量:17630